Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026

Gilead Sciences Inc. (NASDAQ:GILD) has recently been identified as one of the best stocks to watch for the next decade. With a price target increase from $147 to $151 by Morgan Stanley, the company is expected to thrive as biopharma policy uncertainties begin to fade. This positive outlook is based on the anticipation that market attention will shift back to the industry’s financial and operational performance once regulatory and political uncertainties subside.

On December 15, Gilead Sciences Inc. announced positive results from its Phase 3 ARTISTRY-2 clinical trial. The study focused on virologically suppressed adults with HIV-1 who switched from the current standard-of-care, BIKTARVY, to an investigational once-daily, single-tablet regimen combining bictegravir and lenacapavir (BIC/LEN). The trial demonstrated that BIC/LEN was statistically non-inferior to BIKTARVY, meeting the primary efficacy endpoint of maintaining HIV-1 RNA levels below 50 copies/mL at Week 48. These results are a significant advancement in Gilead’s history of HIV innovation and offer a potential new treatment option for individuals living with the virus worldwide.

Gilead plans to use the data from the ARTISTRY-2 trial alongside similar results from the ARTISTRY-1 trial as the foundation for upcoming regulatory submissions. The company aims to present detailed findings at an upcoming scientific congress, further solidifying its position as a leader in HIV treatment innovation.

As a biopharmaceutical company, Gilead Sciences Inc. focuses on discovering, developing, and commercializing medicines to address unmet medical needs globally. With a strong track record of innovation, the company continues to make strides in improving the lives of patients affected by various diseases.

While GILD presents potential as an investment, there are other opportunities to consider. Certain AI stocks may offer greater upside potential and less downside risk. For those interested in exploring undervalued AI stocks that stand to benefit from current trends, a free report on the best short-term AI stock is available for review.

In conclusion, Gilead Sciences Inc. remains a key player in the biopharmaceutical industry with promising developments in HIV treatment. As the company continues to innovate and address unmet medical needs, investors may want to keep an eye on its future growth and potential opportunities in the market.